On Tuesday, Xeris Biopharma Holdings Inc (NASDAQ: XERS) opened lower -7.92% from the last session, before settling in for the closing price of $5.05. Price fluctuations for XERS have ranged from $2.03 to $6.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 136.89% over the past five years. Company’s average yearly earnings per share was noted 79.28% at the time writing. With a float of $147.66 million, this company’s outstanding shares have now reached $156.01 million.
Let’s look at the performance matrix of the company that is accounted for 394 employees. In terms of profitability, gross margin is 80.99%, operating margin of -10.11%, and the pretax margin is -21.41%.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xeris Biopharma Holdings Inc is 7.80%, while institutional ownership is 54.44%. The most recent insider transaction that took place on May 09 ’25, was worth 277,668. Before that another transaction happened on Mar 20 ’25, when Company’s insider sold 40,000 for $5.43, making the entire transaction worth $217,244. This insider now owns 1,353,510 shares in total.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 79.28% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Check out the current performance indicators for Xeris Biopharma Holdings Inc (XERS). In the past quarter, the stock posted a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.30, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 2.57 million, a negative change from its year-to-date volume of 2.6 million. As of the previous 9 days, the stock’s Stochastic %D was 48.17%. Additionally, its Average True Range was 0.27.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 51.54%, which indicates a significant increase from 13.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.44% in the past 14 days, which was lower than the 62.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.73, while its 200-day Moving Average is $3.70. Nevertheless, the first resistance level for the watch stands at $4.95 in the near term. At $5.25, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.44. If the price goes on to break the first support level at $4.46, it is likely to go to the next support level at $4.27. The third support level lies at $3.97 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
There are currently 156,385K shares outstanding in the company with a market cap of 744.72 million. Presently, the company’s annual sales total 203,070 K according to its annual income of -54,840 K. Last quarter, the company’s sales amounted to 60,120 K and its income totaled -9,220 K.
